Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?

Multiple myeloma is a malignancy of immunoglobulin-secreting plasma cells that is now often treated in the newly diagnosed and relapsed and/or refractory settings with monoclonal antibodies targeting lineage-specific markers used either alone or in rationally designed combination regimens. Among the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Upasana, Orlowski, Robert Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145905/
https://www.ncbi.nlm.nih.gov/pubmed/37111346
http://dx.doi.org/10.3390/ph16040590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145905/
https://www.ncbi.nlm.nih.gov/pubmed/37111346
http://dx.doi.org/10.3390/ph16040590

Ejemplares similares